The role of recombinant Human erythropoietin in neonatal anemia

• Main Authors: Dalia M. El-Lahony, Nagwan Y. Saleh, Mona S. Habib, Mohammed A. Shehata, Mahmoud A. El-Hawy
• Format: Article
• Language: English
• Published: Elsevier 2020-09-01
• Series: Hematology/Oncology and Stem Cell Therapy
• Subjects: Erythropoietin(EPO); APO; Neonatal
• Online Access: http://www.sciencedirect.com/science/article/pii/S1658387619300743

Aim: To estimate the blood level of Erythropoietin(EPO) in neonates with anemia of prematurity (APO) and in late hypo-regenerative anemia and to clarify role of EPO in correction of anemia and reducing the number of blood transfusions. Methods: This study was carried out on 60 neonates divided into; group I (30 preterm neonates) with AOP received EPO (250 IU/kg/dose subcutaneously 3 times weekly for 4 weeks), compared to group II (30 neonates) with AOP treated only with blood transfusion. CBC parameters and transfusion requirements were followed during therapy. Serum level of EPO was measured by ELISA technique. Results: By the end of the 4th week of therapy, there was significant increase in group I post r-Hu EPO compared to group II regarding reticulocyte counts (P < 0.001) leading to rise of the Hb (P < 0.001), Hct levels (P < 0.001) with subsequent reduction in the overall number of blood transfusions (P < 0.001). Conclusion: EPO therapy in conjunction with iron, vitamin E and folic acid, stimulated erythropoiesis and significantly reduced the need for blood transfusion in AOP.